% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zeiser:274462,
      author       = {R. Zeiser$^*$ and Y.-B. Chen and N. N. Youssef and F. Ayuk},
      title        = {{P}athophysiology of gastrointestinal acute
                      graft-versus-host disease and the potential role of
                      glucagon-like peptide 2.},
      journal      = {British journal of haematology},
      volume       = {201},
      number       = {4},
      issn         = {0007-1048},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-00607},
      pages        = {620-627},
      year         = {2023},
      note         = {2023 May;201(4):620-627},
      abstract     = {Acute graft-versus-host disease (aGVHD) is a
                      life-threatening complication after allogeneic
                      haematopoietic cell transplantation, with gastrointestinal
                      (GI) tract involvement (GI aGVHD) being one of the leading
                      causes of morbidity and mortality. Whilst systemic steroids
                      are the standard first-line treatment for aGVHD,
                      approximately $50\%$ of patients become steroid refractory
                      (SR), which is associated with poor outcomes. Existing
                      options for SR-GVHD are limited, and there is a significant
                      unmet need for new non-immunosuppressive treatment
                      approaches in patients with GI aGVHD. Here, we review newer
                      concepts in the pathogenesis of GI aGVHD and present the
                      evidence for the role of glucagon-like peptide 2 (GLP-2) in
                      maintaining and protecting GI epithelial cells, including
                      the enterocytes, intestinal stem cells and Paneth cells,
                      which are direct targets of aGVHD. Finally, we discuss the
                      therapeutic rationale for GLP-2 treatment as a tissue
                      regeneration approach and the potential use of the novel
                      GLP-2 analogue apraglutide as an adjunctive treatment for GI
                      aGVHD.},
      subtyp        = {Review Article},
      keywords     = {GVHD (Other) / HSC transplantation (Other) / transplant
                      (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36965050},
      doi          = {10.1111/bjh.18778},
      url          = {https://inrepo02.dkfz.de/record/274462},
}